Loading

Please wait...

Tagamet hb

Generic Name: cimetidine (sye ME ti deen)
Brand Name: Tagamet HB
Physician reviewed Tagamet HB patient information - includes Tagamet HB description, dosage and directions.

Average Savings for cimetidine (generic): 32.71%
  • Prescription Settings
  • X

Prices and coupons of Tagamet hb

Set your location
for drug prices near you

Enter your zip code


Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Tagamet HB is a stomach acid reducer that is used to treat and prevent certain types of stomach ulcer. This medicine is also used to treat gastroesophageal reflux disease (GERD), when stomach acid backs up into the esophagus and causes heartburn. Over-the-counter (nonprescription) Tagamet HB is used to treat heartburn with sour stomach and acid indigestion, or to prevent these conditions when caused by certain foods or beverages. Tagamet HB may also be used for purposes not listed in this medication guide. Learn more

Tagamet hb Side Effects

Tagamet HB Side Effects

Note: This document contains side effect information about cimetidine. Some of the dosage forms listed on this page may not apply to the brand name Tagamet HB.

In Summary

More frequent side effects include: gynecomastia. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to cimetidine: oral liquid and tablets, parenteral injection, parenteral injection for iv infusion only

Side effects include:

Headache, dizziness, somnolence, diarrhea.

With ≥1 month of therapy: gynecomastia.

With IM therapy: transient pain at injection site.

For Healthcare Professionals

Applies to cimetidine: compounding powder, intravenous solution, oral liquid, oral tablet

Renal

Very common (10% or more): Increased plasma creatinine (up to 11%)

Rare (0.01% to 0.1%): Interstitial nephritis

Interstitial nephritis cleared with drug withdrawal.

Creatinine elevations usually occurred during the first week of treatment and were typically non-progressive, with values returning to pretreatment levels during therapy or up to 1 week after stopping treatment.

Gastrointestinal

Common (1% to 10%): Constipation, diarrhea, flatulence, nausea, vomiting

Rare (0.01% to 0.1%): Acute pancreatitis/pancreatitis

Pancreatitis cleared with drug withdrawal.

Musculoskeletal

Common (1% to 10%): Musculoskeletal pain, myalgia/reversible myalgia

Rare (0.01% to 0.1%): Arthralgia/reversible arthralgia, exacerbation of joint symptoms, polymyositis

Nervous system

Common (1% to 10%): Dizziness, drowsiness, headache

Headaches occurred more frequently in patients given 1600 mg/day compared to patients given 800 mg/day.

Somnolence and dizziness were usually mild and have been reported in patients receiving 800 to 1600 mg/day.

Dermatologic

Hypersensitivity vasculitis usually cleared with drug withdrawal.

Common (1% to 10%): Rash/skin rashes

Rare (0.01% to 0.1%): Hypersensitivity vasculitis

Very rare (less than 0.01%): Epidermal necrolysis, erythema multiforme, generalized exfoliative erythroderma, reversible alopecia, severe generalized skin reactions, Stevens-Johnson syndrome

Frequency not reported: Severe skin rash

Other

Fever cleared with drug withdrawal.

Common (1% to 10%): Tiredness

Rare (0.01% to 0.1%): Fever

Psychiatric

Confusional states occurred within 2 to 3 days of starting treatment, were reversible within 3 to 4 days of stopping treatment and were more commonly reported in elderly patients and/or ill patients (e.g., renal dysfunction, organic brain syndrome).

Uncommon (0.1% to 1%): Confusional state, depression, hallucination

Frequency not reported: Agitation, anxiety, disorientation, mental confusion, psychosis

Hepatic

Hepatitis and serum transaminase level elevations cleared with drug withdrawal.

Fatal hepatic effects have occurred with other histamine-2 receptor antagonists.

Severe parenchymal injury is considered highly unlikely due to the predominance of cholestatic features.

There was a report of biopsy-proven periportal hepatic fibrosis in a patient receiving this drug.

Uncommon (0.1% to 1%): Hepatitis, reversible liver damage

Rare (0.01% to 0.1%): Cholestatic effects, increased serum transaminases, mixed cholestatic-hepatocellular effects

Very rare (less than 0.01%): Fatal hepatic effects

Frequency not reported: Periportal hepatic fibrosis, severe parenchymal injury

Hematologic

Uncommon (0.1% to 1%): Leukopenia

Rare (0.01% to 0.1%): Agranulocytosis, aplastic anemia, decreased white blood cell counts, pancytopenia, thrombocytopenia

Very rare (less than 0.01%): Immune hemolytic anemia

Leukopenia and/or thrombocytopenia were reversible with withdrawal of treatment.

Agranulocytosis/decreased white blood cell counts have been reported, with some events recurring upon rechallenge. These events were more commonly reported in patients with serious concomitant illnesses and/or those who received drugs/treatments known to produce neutropenia.

Cardiovascular

Uncommon (0.1% to 1%): Tachycardia

Rare (0.01% to 0.1%): Atrioventricular (AV) heart block/heart block, sinus bradycardia

Genitourinary

Urinary retention cleared with drug withdrawal.

Uncommon (0.1% to 1%): Reversible impotence

Rare (0.01% to 0.1%): Urinary retention

Very rare (less than 0.01%): Galactorrhea

Endocrine

Uncommon (0.1% to 1%): Gynecomastia

Hypersensitivity

Allergic reactions and anaphylaxis usually cleared with drug withdrawal.

Rare (0.01% to 0.1%): Allergic reactions, anaphylaxis

Immunologic

Very rare (less than 0.01%): Strongyloidiasis hyperinfection

Respiratory

In a large epidemiological study, it was suggested that patients taking histamine-2-receptor antagonists had an increased adjusted relative risk of 1.63 (95% confidence interval of 1.07 to 2.48) of developing pneumonia compared to patients who stopped treatment. However, causal relationship between H2RA use and pneumonia has not been established.

Frequency not reported: Pneumonia

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.

Source: Drugs.com Tagamet Hb (www.drugs.com/mtm/tagamet-hb.html).